Arcutis Biotherapeutics

Our 2025 annual report and shareholder letter are now available. Our achievements in 2025 strengthened Arcutis’ position as a leading medical dermatology company. Building on this momentum, we'll continue to grow, expand, and build in 2026. Read more: investors.arcutis.com/financial-info…

#NEWS: We’re excited to be back at @AADskin’s 2026 Annual Meeting and look forward to sharing data from our studies in #AtopicDermatitis, #SeborrheicDermatitis, and #Psoriasis. Learn more: arcutis.com/arcutis-to-pre… #AAD2026 #ClinicalDermatology #ArcutisAtAAD

#NEWS: Pediatric Dermatology published long-term results from the Phase 3 open-label extension study of our once-daily topical cream for the treatment of mild-to-moderate #AtopicDermatitis in children aged 2-5 years. Read more: arcutis.com/arcutis-announ… #PediatricDermatology

#NEWS: We’re thrilled to announce Mas Matsuda, JD’s promotion to EVP and Chief Legal Officer! His leadership and trusted counsel have helped support our growth, and we look forward to his continued impact in this new role. Congratulations, Mas! Read more: arcutis.com/arcutis-announ…

#NEWS: Today we announced the enrollment of the first individual in a Phase 1 study evaluating ARQ-234, a potential biologic treatment for moderate to severe #AtopicDermatitis. Learn more: arcutis.com/arcutis-begins… #ClinicalDermatology

Tomorrow, Arcutis President and CEO Frank Watanabe and Chief Commercial Officer Todd Edwards will be participating in a fireside chat at the TD Cowen 46th Annual Health Care Conference in Boston. More details below. #ClinicalDermatology $ARQT

Arcutis is in Philadelphia for the 2026 @AAAAI_org Annual Meeting, where we’ll be presenting data and connecting with colleagues across the community. We look forward to advancing #MeaningfulInnovation in patient care. #AAAAI26 #ClinicalDermatology

#NEWS: Today, we announced #Q4 2025 and full year 2025 financial results. Read our release for full details and business updates: investors.arcutis.com/news-releases/… $AQRT

#NEWS: Excited to tee-off our partnership with pro-golfer, Max Homa, as part of our Free to Be Me campaign! Learn more about this campaign and Max's journey to manage his seb derm: arcutis.com/professional-g… #ClinicalDermatology #SebDerm

Arcutis CMO Patrick Burnett, MD, PhD, FAAD and CFO Latha Vairavan are participating in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit this week in New York City. Details below. #ClinicalDermatology $ARQT

#NEWS: Today, we shared topline results from the INTEGUMENT-INFANT #ClinicalTrial evaluating our topical cream in infants ages 3-24 months with mild to moderate #AtopicDermatitis. Learn more: arcutis.com/arcutis-announ…

#NEWS: Today, we announced that Arcutis and Kowa have mutually agreed to terminate our promotion agreement. Following the termination, Arcutis plans to assume responsibility for sales and promotion in the pediatric and primary care settings. Read more: arcutis.com/arcutis-biothe…

Aloha! We’re excited to be back in Maui for @MauiDerm Hawaii 2026. We’ll be sharing data, collaborating with peers, and discussing new ideas for driving #MeaningfulInnovation in #dermatology. We look forward to connecting with you in paradise! #ClinicalDermatology

Arcutis is in Maui for @dermsquared’s 2026 Winter Clinical Dermatology Conference! We’ll be sharing data and look forward to connecting with colleagues and industry leaders advancing #MeaningfulInnovation in #MedicalDermatology. #WCH26 #WinterClinicalHawaii #Dermatology

#NEWS: Today we provided our outlook for 2026 including updates on strategy for long-term growth, how we will expand our clinical development, and build our pipeline this year. Read more: arcutis.com/arcutis-highli…

We’re at the 4th Annual @MauiDerm Caribbean 2026 in San Juan, Puerto Rico connecting with dermatology leaders to explore the latest in #dermatology. Our team is excited for the chance to learn, collaborate, and advance clinical care together! #ClinicalDermatology

#NEWS: We’re pleased to welcome Amit Munshi to our Board of Directors, bringing deep expertise and visionary leadership to Arcutis. We also thank Bhaskar Chaudhuri, for many years of significant contributions, dedication, and insights. Read more: arcutis.com/arcutis-streng…

Innovation is more than discovery — it’s about impact. In this video, President & CEO Frank Watanabe shares Arcutis’ goal to reinvigorate innovation and raise the bar in dermatology. #MeaningfulInnovation #ThisIsArcutUS #ClinicalDermatology

#NEWS: The FDA has accepted our sNDA to expand the indication for our topical treatment of #PlaquePsoriasis in children as young as 2 years of age. This milestone reflects our dedication to advancing care in #ClinicalDermatology. Learn more: arcutis.com/fda-accepts-su…

Arcutis is in NYC for ISDS 2025 to present data & join global experts to explore advances in inflammatory skin disease. We’re proud to advance #MeaningfulInnovation to improve outcomes for those living with chronic inflammatory #SkinDiseases. #ISDS2025 #ClinicalDermatology